EyePoint, Inc.
Business
EyePoint, Inc. is a clinical-stage biopharmaceutical company developing sustained-delivery therapeutics for retinal diseases using its proprietary Durasert E™ bioerodible technology platform. The company's lead candidate, DURAVYU™, combines vorolanib (a tyrosine kinase inhibitor) with Durasert E™ for treating wet age-related macular degeneration and diabetic macular edema, currently in Phase 3 trials. EyePoint also operates a commercial manufacturing facility and licenses FDA-approved products (YUTIQ® and ILUVIEN) to partners for royalties.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 31 | 43 | 46 | 41 | 37 | |
| Cost of sales | 2 | 4 | 5 | 8 | 8 | |
| Research and development | 221 | 133 | 65 | 50 | 29 | |
| Sales and marketing | 90,000 | 131,000 | 12 | 26 | 28 | |
| General and administrative | 52 | 52 | 40 | 35 | 26 | |
| Total operating expenses | 275 | 189 | 121 | 141 | 92 | |
| Loss from operations | −243 | −146 | −75 | −100 | −55 | |
| Interest and other income, net | 12 | 15 | 7 | 2 | 292,000 | |
| Interest expense | −33,000 | −14,000 | −1 | — | — | |
| Loss on extinguishment of debt | 0 | 0 | −1 | −2 | 2 | |
| Total other income, net | 12 | 15 | 4 | −3 | −3 | |
| Net loss before income taxes | −232 | −131 | −71 | −102 | — | |
| Provision for income taxes | −279,000 | −90,000 | −83,000 | — | — | |
| Net loss | −232 | −131 | −71 | −102 | −58 | |
| Net loss per share - basic | −3.17 | −2.32 | −1.82 | −2.74 | −2.03 | |
| Net loss per share - diluted | −3.17 | −2.32 | −1.82 | −2.74 | −2.03 | |
| Weighted average common shares outstanding - basic | 73,251 | 56,298 | 38,904 | 37 | 29 | |
| Weighted average common shares outstanding - diluted | 73,251 | 56,298 | 38,904 | 37 | 29 | |
| Unrealized gain (loss) on available-for-sale securities | −67,000 | 164,000 | 78,000 | −55,000 | 0 | |
| Comprehensive income (loss) | −232 | −131 | −71 | −102 | −58 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 102 | 100 | 281 | 96 | — | |
| Marketable securities | 204 | 271 | 50 | 49 | — | |
| Accounts and other receivables, net | 651,000 | 607,000 | 805,000 | 16 | — | |
| Prepaid expenses and other current assets | 20 | 9 | 9 | 10 | — | |
| Inventory | 2 | 2 | 4 | 3 | — | |
| Total current assets | 329 | 383 | 345 | 173 | — | |
| Property and equipment, net | 9 | 8 | 5 | 1 | — | |
| Operating lease right-of-use assets | 20 | 21 | 5 | 6 | 3 | |
| Restricted cash | 150,000 | 150,000 | 150,000 | 150,000 | — | |
| Other assets | 6 | 6 | 0 | — | — | |
| Total assets | 364 | 418 | 355 | 180 | — | |
| Accounts payable | 10 | 12 | 7 | 6 | — | |
| Accrued expenses | 24 | 18 | 18 | 16 | — | |
| Deferred revenue | 0 | 18 | 39 | 1 | — | |
| Other current liabilities | 2 | 1 | 646,000 | 579,000 | — | |
| Total current liabilities | 37 | 49 | 63 | 35 | — | |
| Deferred revenue - noncurrent | 0 | 11 | 21 | 14 | — | |
| Operating lease liabilities - noncurrent | 21 | 22 | 5 | 6 | — | |
| Other noncurrent liabilities | 87,000 | 205,000 | 0 | 600,000 | — | |
| Total liabilities | 58 | 82 | 89 | 84 | — | |
| Contingencies (Note 14) | — | — | — | — | — | |
| Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding | 0 | 0 | 0 | 0 | — | |
| Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 82,826,416 and 68,266,005 shares issued and outstanding at December 31, 2025 and 2024, respectively | 83,000 | 68,000 | 49,000 | 34,000 | — | |
| Additional paid-in capital | 1,410 | 1,208 | 1,008 | 767 | — | |
| Accumulated deficit | −1,105 | −873 | −742 | −671 | — | |
| Accumulated other comprehensive income (loss) | 961,000 | 1 | 864,000 | 786,000 | — | |
| Total stockholders equity | 306 | 337 | 266 | 96 | — | |
| Total liabilities and stockholders equity | 364 | 418 | 355 | 180 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −232 | −131 | −71 | −102 | −58 | |
| Depreciation of property and equipment | 2 | 2 | — | — | — | |
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | −5 | −6 | −856,000 | −558,000 | 628,000 | |
| Stock-based compensation | 28 | 37 | 12 | 14 | 7 | |
| Deferred income tax | 279,000 | 90,000 | 83,000 | — | — | |
| Accounts receivable and other current assets | −11 | −244,000 | 14 | −3 | −11 | |
| Other assets | −113,000 | −6 | 0 | — | — | |
| Inventory | 492,000 | 2 | −2 | −760,000 | 1 | |
| Accounts payable and accrued expenses | 5 | 6 | 2 | 1 | 8 | |
| Right-of-use assets and operating lease liabilities | 500,000 | 2 | −39,000 | 69,000 | −28,000 | |
| Deferred revenue | −29 | −31 | 45 | −868,000 | −931,000 | |
| Other noncurrent liabilities | −33,000 | 0 | — | — | — | |
| Net cash (used in) provided by operating activities | −240 | −126 | 2 | −65 | −50 | |
| Purchases of marketable securities | −252 | −398 | −55 | −139 | −33 | |
| Sales and maturities of marketable securities | 324 | 183 | 55 | 124 | 0 | |
| Purchases of property and equipment | −3 | −4 | −3 | −2 | −156,000 | |
| Proceeds from sale of property and equipment | 155,000 | 0 | — | — | — | |
| Net cash (used in) provided by investing activities | 69 | −219 | −3 | −17 | −33 | |
| Proceeds from issuance of stock | 173 | 163 | 226 | 0 | — | |
| Payment of equity issue costs | −543,000 | −672,000 | −451,000 | — | — | |
| Net settlement of stock units to satisfy statutory tax withholding | −1 | −5 | −169,000 | −295,000 | −150,000 | |
| Proceeds from exercise of stock options and employee stock purchase plan | 2 | 6 | 3 | 395,000 | — | |
| Principal payments on finance lease obligations | −105,000 | −105,000 | −36,000 | −137,000 | −146,000 | |
| Net cash (used in) provided by financing activities | 174 | 164 | 187 | −690,000 | 217 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 2 | −182 | 186 | −83 | 134 | |
| Lease liability arising from obtaining right-of-use assets | 903,000 | 18 | 0 | — | — | |
| Stock issuance costs | 316,000 | 311,000 | 325,000 | 0 | 294,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is EyePoint, Inc.'s CIK number?
EyePoint, Inc.'s SEC CIK number is 0001314102 (1314102). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find EyePoint, Inc.'s SEC filings?
All of EyePoint, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did EyePoint, Inc. last report earnings?
EyePoint, Inc. (EYPT) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-207537). This is EyePoint, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is EyePoint, Inc.'s most recent earnings 8-K?
EyePoint, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-207537. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View EyePoint, Inc.'s latest earnings 8-K →
Look up any company's CIK number →